Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Drug Name | DSP107 |
| Trade Name | |
| Synonyms | DSP-107|DSP 107|SIRPa-4-1BBL DSP107|SIRPa 4-1BBL DSP107 |
| Drug Descriptions |
DSP107 is a bi-functional trimeric fusion protein that consists of extracellular domains of SIRP alpha and 4-1BBL, which blocks the interaction between CD47 and SIRP alpha, and simultaneously activates the co-stimulatory receptor 4-1BB, potentially activating innate and adaptive immune responses, and inducing cytotoxicity and phagocytosis of tumor cells (Cancer Immunol Res 2019;7(2 Suppl):Abstract nr A076; Blood (2020) 136 (Supplement 1): 19-20). |
| DrugClasses | |
| CAS Registry Number | NA |
| NCIT ID | C174171 |
| Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
|---|---|---|---|
| Atezolizumab + DSP107 | Atezolizumab DSP107 | 0 | 2 |
| Azacitidine + DSP107 + Venetoclax | Azacitidine DSP107 Venetoclax | 0 | 1 |
| Cetuximab + DSP107 | Cetuximab DSP107 | 0 | 0 |
| DSP107 | DSP107 | 0 | 1 |
| DSP107 + Rituximab | DSP107 Rituximab | 0 | 0 |